Introduction to PDABs: How US states are addressing high-cost prescription drugs
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
CRA is a proud sponsor of the the largest and most established orphan drug & rare disease meeting of its kind across the globe. From cell and gene therapy,...
Tim Wilsdon moderates the panel discussion following the presentation on “Implementing next steps for AD Policy at EU and Member State-level, and the role of...
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...